Physician profile
Patrick D Gonzales
NPI 1194751289
$4,551.23
in general payments reported to CMS, 2019-2025
29 companies · $942 in 2025
The $942 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $221 · 2020: $766 · 2021: $1,176 · 2022: $287 · 2023: $620 · 2024: $541 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,101.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,038.62 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $572.94 | 2019-2025 | Jardiance, Tradjenta |
| Novo Nordisk INC | $343.35 | 2019-2025 | Ozempic |
| Glaxosmithkline, LLC. | $314.43 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $280.16 | 2020-2024 | |
| Medtronic, INC. | $277.46 | 2023-2024 | Intellis Adaptivestim |
| Janssen Pharmaceuticals, INC | $272.26 | 2019-2022 | |
| Astellas Pharma US INC | $210.07 | 2019-2021 | |
| Pfizer INC. | $208.74 | 2019-2024 | |
| Amgen INC. | $194.00 | 2020-2025 | Otezla, Repatha, Prolia |
| Mannkind Corporation | $164.34 | 2020-2023 | Afrezza |
| Horizon Therapeutics Plc | $153.97 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $101.80 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Lilly USA, LLC | $61.00 | 2023-2024 | Jardiance, Emgality |
| Edwards Lifesciences Corporation | $41.70 | 2024-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.19 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $29.48 | 2024 | Arcalyst |
| Abbott Laboratories | $27.90 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $27.04 | 2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $24.75 | 2021 | |
| Allergan, INC. | $23.96 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.47 | 2021 | |
| Si-Bone, INC. | $22.01 | 2023 | |
| Idorsia Pharmaceuticals US INC | $21.27 | 2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $20.26 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.54 | 2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $14.04 | 2024 | Gemtesa |
| Intra-Sana Laboratories | $13.25 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| E.R. Squibb & Sons, L.L.C. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gonzales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.